EUVIMEDEUVIMED entdecken
Open Access

Intravesical oncolytic virotherapy and immunotherapy for non‐muscle ‐invasive bladder cancer mouse model

Woodson W Smelser, Jian Wang, Kristen M Ogden, Sam S Chang, Austin N Kirschner iD

BJU International · 2023

DOI: 10.1111/bju.16012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJU International, 2023. Verfasst von Woodson W Smelser und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Urology, Washington University in St. Louis, St. Louis, MI, USA. Hauptthemen laut MEDLINE: Oncolytic Virotherapy, Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIAID NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To test if intravesical instillation of both an anti‐programmed cell death protein 1 (PD‐1) inhibitor and an oncolytic reovirus would demonstrate a greater effect than either treatment alone, as non‐muscle‐invasive bladder cancer that is refractory to intravesical bacillus Calmette–Guérin can be treated by systemic anti‐PD‐1 immunotherapy and we previously demonstrated improved overall survival (OS) with six once‐weekly instillations of intravesical anti‐PD‐1 in a murine model. Materials and Methods Using an orthotopic syngeneic C3H murine model of MBT2 urothelial bladder cancer, groups of 10 mice were compared between no treatment, intravesical anti‐PD‐1, intravesical oncolytic reovirus, or intravesical reovirus + anti‐PD‐1. A single intravesical treatment session was given. The primary outcome was OS, and the secondary outcomes included long‐term immunity and tumour–immune profile.

Results

With a median follow‐up of 9 months, all mice that received no treatment died with a median survival of 41 days, while the comparison median OS was not reached for reovirus (hazard ratio [HR] 14.4, 95% confidence interval [CI] 3.9–32.6; P < 0.001), anti‐PD‐1 (HR 28.4, 95% CI 7.0–115.9; P < 0.001), and reovirus + anti‐PD‐1 (HR 28.4, 95% CI 7.0–115.9; P < 0.001). Monotherapy with anti‐PD‐1 or reovirus demonstrated no significant differences in survival ( P = 0.067). Mass cytometry showed that reovirus + anti‐PD‐1 treatment enriched monocytes and decreased myeloid‐derived suppressor cells, generating an immuno‐responsive tumour microenvironment. Depletion of CD8 + T cells eliminated the survival advantage provided by the intravesical treatment.

Conclusions

Treatment of murine orthotopic bladder tumours with a single instillation of intravesical reovirus, anti‐PD‐1 antibody, or the combination confers superior survival compared to controls. Tumour–immune microenvironment differences indicated myeloid‐derived suppressor cells and CD8 + T cells mediate the treatment response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oncolytic VirotherapyNon-Muscle Invasive Bladder NeoplasmsUrinary Bladder NeoplasmsMiceAnimalsDisease Models, AnimalCD8-Positive T-LymphocytesMice, Inbred C3HImmunotherapyAdministration, IntravesicalBCG VaccineTumor Microenvironment

Stichwörter der Autor:innen

Intravesical therapyOncolytic therapygenitourinary cancer/bladder cancerimmunotherapyorganism/animal model of cancer

Substanzen

BCG Vaccine

Autor:innen und Institutionen

  • Department of Surgery, Division of Urology, Washington University in St. Louis, St. Louis, MI, USA.
  • Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Department of Pediatrics, Nashville, TN, USA.
  • Department of Pathology, Microbiology, and Immunology, Nashville, TN, USA.

ORCID-Profile: Austin N Kirschner

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • National Cancer Institute
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Smelser, W. W., Wang, J., Ogden, K. M., Chang, S. S., & Kirschner, A. N. (2023). Intravesical oncolytic virotherapy and immunotherapy for non‐muscle ‐invasive bladder cancer mouse model. BJU International. https://doi.org/10.1111/bju.16012

Vancouver

Smelser WW, Wang J, Ogden KM, Chang SS, Kirschner AN. Intravesical oncolytic virotherapy and immunotherapy for non‐muscle ‐invasive bladder cancer mouse model. BJU International. 2023. doi:10.1111/bju.16012

BibTeX
@article{Smelser2023,
  author = {Smelser, Woodson W and Wang, Jian and Ogden, Kristen M and Chang, Sam S and Kirschner, Austin N},
  title = {Intravesical oncolytic virotherapy and immunotherapy for non‐muscle ‐invasive bladder cancer mouse model},
  journal = {BJU International},
  year = {2023},
  doi = {10.1111/bju.16012}
}
Kostenlos starten →